报价延迟最少15分钟:2026/04/21 19:46 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.52 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.09/-0.89
|
|
企业价值
46.15M
|
| 资产负债 |
|
每股账面净值
0.25
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
90.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors. |
